These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 14744176)

  • 1. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents.
    Richardson MA; Small AM; Read LL; Chao HM; Clelland JD
    J Clin Psychiatry; 2004 Jan; 65(1):92-6. PubMed ID: 14744176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Branched chain amino acids decrease tardive dyskinesia symptoms.
    Richardson MA; Bevans ML; Weber JB; Gonzalez JJ; Flynn CJ; Amira L; Read LL; Suckow RF; Maher TJ
    Psychopharmacology (Berl); 1999 Apr; 143(4):358-64. PubMed ID: 10367552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of the branched-chain amino acids in the treatment of tardive dyskinesia in men.
    Richardson MA; Bevans ML; Read LL; Chao HM; Clelland JD; Suckow RF; Maher TJ; Citrome L
    Am J Psychiatry; 2003 Jun; 160(6):1117-24. PubMed ID: 12777270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head Injury Treatment With Healthy and Advanced Dietary Supplements: A Pilot Randomized Controlled Trial of the Tolerability, Safety, and Efficacy of Branched Chain Amino Acids in the Treatment of Concussion in Adolescents and Young Adults.
    Corwin DJ; Myers SR; Arbogast KB; Lim MM; Elliott JE; Metzger KB; LeRoux P; Elkind J; Metheny H; Berg J; Pettijohn K; Master CL; Kirschen MP; Cohen AS
    J Neurotrauma; 2024 Jun; 41(11-12):1299-1309. PubMed ID: 38468511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Kinon BJ; Jeste DV; Kollack-Walker S; Stauffer V; Liu-Seifert H
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep; 28(6):985-96. PubMed ID: 15380859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
    Anderson KE; Stamler D; Davis MD; Factor SA; Hauser RA; Isojärvi J; Jarskog LF; Jimenez-Shahed J; Kumar R; McEvoy JP; Ochudlo S; Ondo WG; Fernandez HH
    Lancet Psychiatry; 2017 Aug; 4(8):595-604. PubMed ID: 28668671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a branched-chain amino acid drink in mania.
    Scarna A; Gijsman HJ; McTavish SF; Harmer CJ; Cowen PJ; Goodwin GM
    Br J Psychiatry; 2003 Mar; 182():210-3. PubMed ID: 12611783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Branched-chain amino acids supplementation attenuates the accumulation of blood lactate dehydrogenase during distance running.
    Koba T; Hamada K; Sakurai M; Matsumoto K; Hayase H; Imaizumi K; Tsujimoto H; Mitsuzono R
    J Sports Med Phys Fitness; 2007 Sep; 47(3):316-22. PubMed ID: 17641599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral supplementation of branched-chain amino acid improves nutritional status in elderly patients on chronic haemodialysis.
    Hiroshige K; Sonta T; Suda T; Kanegae K; Ohtani A
    Nephrol Dial Transplant; 2001 Sep; 16(9):1856-62. PubMed ID: 11522870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU; Josiassen RC; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):53-60. PubMed ID: 28839340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
    Kane JM; Correll CU; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):69-76. PubMed ID: 28839342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China.
    Cui YH; Zheng Y; Yang YP; Liu J; Li J
    J Child Adolesc Psychopharmacol; 2010 Aug; 20(4):291-8. PubMed ID: 20807067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Branched-chain amino acids for people with hepatic encephalopathy.
    Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
    Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
    Preskorn SH; Macaluso M
    J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of branched-chain amino acid supplementation after radiofrequency ablation for hepatocellular carcinoma: A randomized trial.
    Nojiri S; Fujiwara K; Shinkai N; Iio E; Joh T
    Nutrition; 2017 Jan; 33():20-27. PubMed ID: 27908546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Total branched-chain amino acids requirement in patients with maple syrup urine disease by use of indicator amino acid oxidation with L-[1-13C]phenylalanine.
    Riazi R; Rafii M; Clarke JT; Wykes LJ; Ball RO; Pencharz PB
    Am J Physiol Endocrinol Metab; 2004 Jul; 287(1):E142-9. PubMed ID: 14970005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Branched-chain amino acid therapy for spinocerebellar degeneration: a pilot clinical crossover trial.
    Mori N; Adachi Y; Takeshima T; Kashiwaya Y; Okada A; Nakashima K
    Intern Med; 1999 May; 38(5):401-6. PubMed ID: 10397076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.